GT200000099A - Combinacion de inhibidores de mtp e inhibidores de hmg - coa reductasa y su uso en medicamentos. - Google Patents
Combinacion de inhibidores de mtp e inhibidores de hmg - coa reductasa y su uso en medicamentos.Info
- Publication number
- GT200000099A GT200000099A GT200000099A GT200000099A GT200000099A GT 200000099 A GT200000099 A GT 200000099A GT 200000099 A GT200000099 A GT 200000099A GT 200000099 A GT200000099 A GT 200000099A GT 200000099 A GT200000099 A GT 200000099A
- Authority
- GT
- Guatemala
- Prior art keywords
- hydropycles
- combination
- inhibitors
- hydropylum
- disorders
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title abstract 4
- 239000003814 drug Substances 0.000 title abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 208000035475 disorder Diseases 0.000 abstract 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 abstract 2
- 206010002383 Angina Pectoris Diseases 0.000 abstract 1
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 abstract 1
- XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 abstract 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 abstract 1
- 102000004877 Insulin Human genes 0.000 abstract 1
- 108090001061 Insulin Proteins 0.000 abstract 1
- 208000001647 Renal Insufficiency Diseases 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 229960005370 atorvastatin Drugs 0.000 abstract 1
- 229960005110 cerivastatin Drugs 0.000 abstract 1
- SEERZIQQUAZTOL-ANMDKAQQSA-N cerivastatin Chemical compound COCC1=C(C(C)C)N=C(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)=C1C1=CC=C(F)C=C1 SEERZIQQUAZTOL-ANMDKAQQSA-N 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 208000029078 coronary artery disease Diseases 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 abstract 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 abstract 1
- 229940125396 insulin Drugs 0.000 abstract 1
- 201000006370 kidney failure Diseases 0.000 abstract 1
- 230000037356 lipid metabolism Effects 0.000 abstract 1
- 150000002632 lipids Chemical class 0.000 abstract 1
- 230000004060 metabolic process Effects 0.000 abstract 1
- 238000001228 spectrum Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
LA INVENCION SE REFIERE AL USO DE UNA COMBINACION DE AL MENOS UN INHIBIDOR DE MTP (CLASIFICADAS EN GENERAL COMO "ESTATINAS" UTILIZADAS CONVENCIONALMENTE EN FORMA DE LACTONAS; ENTRE LAS DE MAYOR PREFERENCIA SE ENCUENTRAN LA ATORVASTATINA, CERIVASTATINA, FLUVASTATINA, LOVASTATINA, ETC. COMPONENTE A ) SELECCIONADO Y UN INHIBIDOR DE HMG COA REDUCTASA ( RELACIONADOS CON PIRIDINAS SUSTITUIDAS O DERIVADOS DEL ACIDO PIRIDILDIHIDROXI HEPTENOICO COMPONENTE B ). LA INVENCION SE REFIERE A MEDICAMENTOS QUE CONTIENEN ESTA COMBINACION Y A SU OBTENCION. VER FORMULAS DE LOS COMPUESTOS PREFERIDOS. LAS COMBINACIONES REIVINDICADAS SEGUN LA INVENCION MUESTRAN UN AMPLIO Y MULTIPLE ESPECTRO DE ACTIVIDAD. PUEDEN UTILIZARSE POR EJEMPLO, PARA EL TRATAMIENTO Y/O PROFILAXIS DE ARTERIOESCLEROSIS, ATAQUE APOPLEJICO, ANGINA, ENFERMEDADES CORONARIAS, INFARTOS, TRASTORNOS DEL METABOLISMO DE LAS GRASAS, AUMENTO DE LIPIDOS SERICOS, HIPERLIPOPROTEINEMIA, HIPERCOLESTEROLNEMIA, AUMENTO DE LOS TRIGLICERIDOS SERICOS, RESISTENCIA A LA INSULINA, DIABETES, TRASTORNOS DEL METABOLISMO DE LOS LIPIDOS, INSUFICIENCIA RENAL, HEPATOMAS Y PLASMACITOMAS.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19929065A DE19929065A1 (de) | 1999-06-25 | 1999-06-25 | Kombination von MTP-Inhibitoren und HMG-CoA-Reduktase-Inhibitoren und ihre Verwendung in Arzneimitteln |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| GT200000099A true GT200000099A (es) | 2001-12-13 |
Family
ID=7912459
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GT200000099A GT200000099A (es) | 1999-06-25 | 2000-06-21 | Combinacion de inhibidores de mtp e inhibidores de hmg - coa reductasa y su uso en medicamentos. |
Country Status (12)
| Country | Link |
|---|---|
| EP (1) | EP1196194A2 (es) |
| JP (1) | JP2003503342A (es) |
| AR (1) | AR028996A1 (es) |
| AU (1) | AU5680900A (es) |
| CA (1) | CA2376881A1 (es) |
| DE (1) | DE19929065A1 (es) |
| DO (1) | DOP2000000022A (es) |
| GT (1) | GT200000099A (es) |
| PE (1) | PE20010302A1 (es) |
| SV (1) | SV2004000109A (es) |
| UY (1) | UY26218A1 (es) |
| WO (1) | WO2001000183A2 (es) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10030375A1 (de) * | 2000-06-21 | 2002-01-03 | Bayer Ag | Verwendung von MTP-Inhibitoren zur Senkung von ppTRL |
| IL161134A0 (en) * | 2002-02-28 | 2004-08-31 | Japan Tobacco Inc | Ester compound and medical use thereof |
| EP1669345A4 (en) | 2003-08-29 | 2008-02-20 | Japan Tobacco Inc | ESTER DERIVATIVE AND MEDICAL USE THEREOF |
| US8101774B2 (en) | 2004-10-18 | 2012-01-24 | Japan Tobacco Inc. | Ester derivatives and medicinal use thereof |
| FR2884831B1 (fr) * | 2005-04-22 | 2007-08-10 | Merck Sante Soc Par Actions Si | Methode de criblage de composes inhibiteurs de la mtp |
| DE102011007272A1 (de) | 2011-04-13 | 2012-10-18 | Bayer Pharma Aktiengesellschaft | Verzweigte 3-Phenylpropionsäure-Derivate und ihre Verwendung |
| US10905667B2 (en) | 2018-07-24 | 2021-02-02 | Bayer Pharma Aktiengesellschaft | Orally administrable modified-release pharmaceutical dosage form |
| CN109053927A (zh) * | 2018-08-08 | 2018-12-21 | 中山大学 | 一种含维生素b12基团的两亲性海藻酸钠衍生物及其制备方法和应用 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4435477A1 (de) * | 1994-10-04 | 1996-04-11 | Bayer Ag | Cycloalkano-indol- und -azaindol-derivate |
| DE19546919A1 (de) * | 1995-12-15 | 1997-06-19 | Bayer Ag | N-Heterocyclisch substituierte Phenylessigsäure-Derivate |
| DE19546918A1 (de) * | 1995-12-15 | 1997-06-19 | Bayer Ag | Bicyclische Heterocyclen |
| DE19615265A1 (de) * | 1996-04-18 | 1997-12-04 | Bayer Ag | Neue Pyridazino-, Pyrimido-, Pyrazino- und Triazino-indole |
| BR9714364A (pt) * | 1996-11-27 | 2000-03-21 | Pfizer | Amidas inibidoras da secreção de apo b/mtp |
| CA2286341A1 (en) * | 1997-05-01 | 1998-11-12 | John R. Ii Wetterau | Mtp inhibitors and fat soluble vitamin therapeutic combinations to lower serum lipid levels |
-
1999
- 1999-06-25 DE DE19929065A patent/DE19929065A1/de not_active Withdrawn
-
2000
- 2000-06-13 AU AU56809/00A patent/AU5680900A/en not_active Abandoned
- 2000-06-13 WO PCT/EP2000/005410 patent/WO2001000183A2/de not_active Ceased
- 2000-06-13 CA CA002376881A patent/CA2376881A1/en not_active Abandoned
- 2000-06-13 EP EP00942056A patent/EP1196194A2/de not_active Withdrawn
- 2000-06-13 JP JP2001505893A patent/JP2003503342A/ja active Pending
- 2000-06-21 GT GT200000099A patent/GT200000099A/es unknown
- 2000-06-22 AR ARP000103129A patent/AR028996A1/es unknown
- 2000-06-23 PE PE2000000625A patent/PE20010302A1/es not_active Application Discontinuation
- 2000-06-23 SV SV2000000109A patent/SV2004000109A/es unknown
- 2000-06-23 UY UY26218A patent/UY26218A1/es not_active Application Discontinuation
-
2008
- 2008-04-11 DO DO2000000022A patent/DOP2000000022A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2001000183A3 (de) | 2001-05-10 |
| PE20010302A1 (es) | 2001-04-12 |
| EP1196194A2 (de) | 2002-04-17 |
| CA2376881A1 (en) | 2001-01-04 |
| WO2001000183A2 (de) | 2001-01-04 |
| UY26218A1 (es) | 2001-01-31 |
| DE19929065A1 (de) | 2000-12-28 |
| AR028996A1 (es) | 2003-06-04 |
| AU5680900A (en) | 2001-01-31 |
| DOP2000000022A (es) | 2008-08-15 |
| JP2003503342A (ja) | 2003-01-28 |
| SV2004000109A (es) | 2004-05-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR0207726A (pt) | Sais farmacêuticos | |
| BR0210139A (pt) | Composições farmacêuticas | |
| CY1106996T1 (el) | Δισκιο με υψηλο φορτιο φαρμακου | |
| GT200600426A (es) | Formulacion novedosa | |
| CL2009000967A1 (es) | Compuesto 4-ciclobutil-n-((2s,5r)-5-hidroxi-2-adamantil)-2-morfolin-4-ilpiridin-5-carboxamida, inhibidor de la enzima 11betahsd1; composicion farmaceutica que lo comprende; y su uso en un procedimiento de tratamiento profilactico o terapeutico de un animal de sangre caliente. | |
| UY26092A1 (es) | Uso de inhibidores de cyp2d6 en terapias de combinacion | |
| BR0315296A (pt) | Derivados do ciclohexanol espirocìclicos | |
| SG161256A1 (en) | Oral pharmaceutical formulations comprising fenofibric acid and/or its salts | |
| UY26776A1 (es) | Inhibidores de 3-hidroxi-3-metilglutaril-coenzima a reductasa y métodos. | |
| GT200300123A (es) | Combinaciones de productos activos fungicidas | |
| MA28921B1 (fr) | Derive heterocyclique azote et medicament le contenant en tant que principe actif | |
| EE200100405A (et) | 3-hüdroksü-3-metüülglutarüüli koensüümi kasutamine reduktaasi inhibiitorina ravimi valmistamiseks diabeetilise neuropaatia raviks | |
| BR0017030B8 (pt) | derivados de tiazolilamida, processo para sua preparação, composição farmacêutica que os compreende e uso dos mesmos | |
| CR10032A (es) | Preparación sólida | |
| MA30725B1 (fr) | Administration d'inhibiteurs de la dipeptidyl peptidase | |
| MX243369B (es) | Composicion pesticida que comprende un ester lactato como inhibidor de crecimiento de cristal. | |
| HN2002000198A (es) | Composiciones farmaceuticas de amlodipina y atorvastatina | |
| MA32929B1 (fr) | Lactames en tant qu'inhibiteurs de bêta-sécrétase | |
| EP1864649A3 (fr) | Composé de type bis-urée, composition le comprenant, utilisation et procédé de traitement cosmétique | |
| GT200000099A (es) | Combinacion de inhibidores de mtp e inhibidores de hmg - coa reductasa y su uso en medicamentos. | |
| BRPI0515645A (pt) | métodos terapêuticos, composições, compostos e usos de compostos | |
| BRPI0416287A (pt) | compostos, processo para a manufatura dos mesmos, composições farmacêuticas que os compreendem, método para o tratamento e/ou prevenção de enfermidades que são moduladas por inibidores de accß e sua utilização | |
| CR5837A (es) | Combinaciones fungicidas que comprenden derivados de aceidofenilacrilico | |
| EE05085B1 (et) | Pridiin-1-oksiidderivaat ja meetod selle muutmiseks farmatseutiliselt efektiivseteks henditeks | |
| MX2007006279A (es) | Composiciones farmaceuticas que comprenden inhibidores de nep, inhibidores del sistema de produccion de endotelina endogena, e inhibidores de hmg coa-reductasa. |